Cis-Compound Mutations are Prevalent in Triple Negative Breast Cancer and Can Drive Tumor Progression

Citations Over Time

Abstract

About 16% of breast cancers fall into a clinically aggressive category designated triple negative (TNBC) due to a lack of ERBB2, estrogen receptor and progesterone receptor expression 1-3 . The mutational spectrum of TNBC has been characterized as part of The Cancer Genome Atlas (TCGA) 4 ; however, snapshots of primary tumors cannot reveal the mechanisms by which TNBCs progress and spread. To address this limitation we initiated the Intensive Trial of OMics in Cancer (ITOMIC)-001, in which patients with metastatic TNBC undergo multiple biopsies over space and time 5 . Whole exome sequencing (WES) of 67 samples from 11 patients identified 426 genes containing multiple distinct single nucleotide variants (SNVs) within the same sample, instances we term Multiple SNVs affecting the Same Gene and Sample (MSSGS). We find that >90% of MSSGS result from cis-compound mutations (in which both SNVs affect the same allele), that MSSGS comprised of SNVs affecting adjacent nucleotides arise from single mutational events, and that most other MSSGS result from the sequential acquisition of SNVs. Some MSSGS drive cancer progression, as exemplified by a TNBC driven by FGFR2(S252W;Y375C). MSSGS are more prevalent in TNBC than other breast cancer subtypes and occur at higher-than-expected frequencies across TNBC samples within TCGA. MSSGS may denote genes that play as yet unrecognized roles in cancer progression.

Related Papers

• → Trichostatin A inhibits proliferation of triple negative breast cancer cells by inducing cell cycle arrest and apoptosis(2018)19 cited
• → Analysis of the clinicopathologic features and prognosis in triple-negative breast cancer(2008)1 cited
• → A comparative study of clinicopathological characteristics and expression of basal markers (CK5/6 & EGFR) in triple negative and non triple negative breast carcinomas in Kashmir valley.(2017)1 cited
• → A comparison of triple negative versus triple positive breast cancers(2011)
• Clinicopathologic Features and Prognosis of Triple Negative Breast Cancer(2008)